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Abstract
Background: Implantable cardioverter defibrillator (ICD) implantation is associated with driving restrictions which
may have profound effects on the patient’s life. However, there is limited patient-reported data on the information
given about driving restrictions, the adherence to the restrictions, the incidence of arrhythmic symptoms while
driving, and the driving restrictions’ effect on ICD patients’ daily life and quality of life factors. A specific questionnaire
was designed to investigate these objectives, intended for use in a nationwide ICD cohort.
Methods: The conceptual framework based on literature review and expert opinion was refined in qualitative semi-
structured focus group interviews with ten ICD patients. Content validity was pursued through pre-testing, including
expert review and 28 cognitive interviews with patients at all ICD implanting centres in Denmark. Finally, the Danish
Pacemaker and ICD registry was used to randomly select 50 ICD patients with a first-time implantation between
January 1, 2013 and November 30, 2016 for pilot testing, followed by a test-retest on 25 respondents. Test-retest
agreement was assessed using kappa statistics or intraclass correlation coefficients.
Results: The pilot test achieved a response rate of 78%, whereof the majority were web-based (69%). Only 49%
stated they had been informed about any driving restrictions after ICD implantation, whereas the number was
75% after appropriate ICD shock. Among respondents, 95% had resumed private driving, ranging from 1 to 90
days after ICD implantation. In those informed of a significant (≥ 1 month) driving ban, 55% stated the driving
restrictions had impeded with daily life, especially due to limitations in maintaining employment or getting to/
from work and 25% admitted they had knowingly been driving during the restricted period. There were six
episodes of dizziness or palpitations not necessitating stopping the vehicle. Test-retest demonstrated good
agreement of questionnaire items, with 69% of Kappa coefficients above 0.60.
Conclusions: We have developed a comprehensive questionnaire on ICD patients’ perspective on driving.
Pre-testing and pilot testing demonstrated good content validity, feasible data collection methods, and a
robust response rate. Thus, we believe the final questionnaire, distributed to almost 4000 ICD patients, will
capture essential evidence to help inform driving guidelines in this population.
Keywords: Implantable cardioverter defibrillators, Driving restrictions, Traffic safety, Patient-reported
outcomes, Questionnaire
* Correspondence: jennybjerre@gmail.com
1Department of Cardiology, Cardiovascular Research, Copenhagen University
Hospital Herlev-Gentofte, Kildegaardsvej 28, 2900 Hellerup, Denmark
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bjerre et al. BMC Cardiovascular Disorders          (2018) 18:212 
https://doi.org/10.1186/s12872-018-0949-3
Background
Implantable cardioverter defibrillators (ICDs) are ef-
fective in preventing sudden cardiac death, both in pa-
tients who have survived a life-threatening arrhythmia
(secondary prevention) and in patients who are at
increased risk of life-threatening arrhythmias (primary
prevention) [1–3]. However, since the early days of
ICD treatment, driving following ICD implantation
and ICD therapy has been controversial. The concern
is that the underlying heart condition may cause an
arrhythmia, potentially incapacitating the patient
while operating a motor vehicle and causing harm to
the patient or others. Hence, scientific societies have
developed statements on the issue [4, 5]: The current
European recommendations advise a four-week
driving restriction following primary prevention ICD
implantation and three-months restriction following
secondary prevention ICD implantation as well as
after appropriate ICD therapy [5]. In Denmark, primary
prevention patients can resume driving 1 week following
implantation, granted home-monitoring is established [6].
Professional driving and driving of large vehicles (> 3.5
metric tonnes) is permanently restricted [5, 6].
There is an overall paucity of research involving
patient-reported outcomes in this area. The few avail-
able studies date back to the 1990s and were performed
in small and selected patient populations, predomin-
antly including secondary prevention patients. Notably,
authors have not reported their methods for developing
and testing the questionnaires and rarely presented the
questionnaires themselves. These studies reported that
information given on driving restrictions is often either
lacking or cannot be recalled by the patients [7, 8], and
even when instructed not to drive, adherence to the
instructions is minimal [7–11]. Moreover, evidence sug-
gest that driving restrictions following ICD implant-
ation negatively impacts the patients’ quality of life
(QoL) [12].
In questionnaire research, it is pivotal that the ques-
tions asked are both relevant and comprehensive for the
objective of the study - a measure of content validity.
Likewise, the questionnaire items should be understand-
able and unambiguous for the target population, war-
ranting thorough pre-testing of the measure before final
application. Lastly, data collection procedures should be
evaluated through a pilot test, to secure sufficient and
analyzable responses.
We aimed to develop a questionnaire investigating ICD
patients’ experiences with driving and driving restrictions.
The intended use was for a cross-sectional investiga-
tion in a nationwide Danish ICD cohort. This paper
describes the process of developing and pre-testing
the questionnaire and ultimately presents selected
results from a pilot test.
Methods
The International Society for Quality of Life Research
(ISO-QOL) recommendations for patient-reported
outcome measures were used as a manual to guide
questionnaire development and testing [13]. These rec-
ommendations have been developed with the aim to
define minimum measurement standards to promote
appropriate use of patient-reported outcomes research.
Figure 1 demonstrates a flow chart of questionnaire
development.
Problem formulation
Initially, we defined four specific objectives for the ques-
tionnaire: (1) Quantify the amount of information given to
ICD patients on driving restrictions following ICD im-
plantation and/or ICD shock; (2) Investigate whether ICD
patients adhere to driving restrictions and which factors
are associated with adherence to driving restrictions; (3)
Determine what proportion of Danish ICD patients have
experienced an ICD shock or cardiac symptoms of pos-
sible arrhythmia while driving, and whether these symp-
toms resulted in a motor vehicle accident; and (4) Identify
whether driving restrictions influence factors associated
with patient QoL.
Conceptualization: Literature and experts
Based on expert opinion and following review of the exist-
ing literature on driving following ICD implantation, an
Fig. 1 Overview of the questionnaire developmental process
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initial conceptual framework was developed which was
successively refined in qualitative semi-structured focus
group interviews. In summary, through conceptualization,
specific variables were defined which could subsequently
be transformed into items, thus connecting the research
objectives with the content of the questionnaire. Add-
itional file 1: Table S1 presents our research aims, hypoth-
eses, concepts and their corresponding variable definitions
as well as questionnaire item numbers. For example, the
concept “Information about driving restrictions after ICD
implantation” resulted in three variable definitions: (1)
Whether the patient held a valid private driver’s license
(Group 1: car, motorcycle, tractor) during the 6 months
leading up to ICD implantation; (2) Whether the patient
held a valid Group 2 driver’s license (Group 2: truck, bus
or any vehicle for passenger transportation) during the 6
months leading up to ICD implantation; (3) Whether the
patient was informed about driving restrictions following
ICD implantation (for both Group 1 and Group 2) by
health personnel (doctors, nurses and ICD technicians)
during the hospitalization for ICD implantation.
A few concepts and variable definitions merit further
elaboration: First, in order to compare questionnaire
responses with current guideline recommendations, we
chose to define private and professional driving based on
the definitions in the European Heart Rhythm Associa-
tion’s recommendations for driving with ICDs and
adapted by the Danish Society of Cardiology [5, 6]. For
our aim of investigating the driving restrictions’ influ-
ence on QoL factors, we were inspired by the World
Health Organization’s six proposed domains of QoL
[14]. From the 24 facets of QoL proposed, we predicted
that 10 could be affected by driving restrictions: negative
feelings, positive feelings and self-esteem (psychological
domain); mobility, activities of daily living and work
capacity (level of independence domain); personal rela-
tionships and social support (social relationship domain);
participation in and opportunities for recreation/leisure
and transport (environment domain).
Conceptualization: Focus group interviews
To uncover unknown concepts related to driving follow-
ing ICD implantation, we performed three focus group
interviews with ten contemporary Danish ICD patients
(20% female, median age 62 years, 50% primary preven-
tion ICD indication). The participants were recruited
from the outpatient clinic at a university hospital in The
Capital Region of Denmark and purposive maximum
sampling was used to achieve variation in pre-specified
variables, including sex, age, ICD indication, previous
ICD therapy and geographic residence. Briefly, the quali-
tative setting allowed ICD patients to elaborate on their
perceptions and experiences with driving and the driving
restrictions. Further, we could observe the social and
cultural norms within groups of ICD patients and thus
gain essential knowledge on what wording to use and
how to approach certain delicate questions, such as ad-
herence to driving restrictions [15].
Operationalization
We followed general technical rules for valid question-
naire design. Initially, the items were grouped into
themes using a strategic order, taking into account spill
over effects and placement of sensitive questions. Thus,
the first questions were considered easy, whereas com-
plexity increased throughout the questionnaire. Respon-
dents were asked when they had resumed driving after
ICD implantation or ICD shock, before the questions
about what information on driving restrictions they had
received. Intentionally, direct questions about adherence
to driving restrictions were placed at the end of the
questionnaire. Since not all questions were relevant for
everyone, e.g. the majority of ICD patients have not
experienced an ICD shock, branching methods were
applied to guide the respondents through the question-
naire. For instance, following a few background ques-
tions (about self-assessed health, educational attainment,
and employment status), respondents without a valid
driver’s license at time of ICD implantation were guided
to the end of the questionnaire. Lastly, due to the sensi-
tive nature of some of the questions, we chose to make
all items voluntary including a possibility of skipping
questions in the web-based questionnaire.
Question formulations were kept short and words with
connotations were excluded. Help texts were included if
deemed necessary. In order to minimize recall bias, we
defined four distinct recall periods (which were con-
firmed realistic during focus groups) depending on the
objective of the question: “the six months leading up to
ICD implantation”, “at the time of ICD implantation”,
“in periods with driving restrictions”, and “during the
previous month.” Text including recall periods was
underscored. Response categories were tailored to the
question type: for factual questions, we particularly
aimed for exhaustive and mutually exclusive response
categories, whereas the focus for opinion questions was
to achieve balance in the response categories. For poten-
tially sensitive questions, including questions about driv-
ing behaviour and the driving restrictions’ influence on
factors related to QoL, we chose to express questions as
opinions with corresponding Likert scale response cat-
egories (strongly agree to strongly disagree) [16], as op-
posed to factual questions with Yes/No response
categories. Likert scale variation was kept minimal with
either three- or five-point scales. Likewise, open re-
sponse categories were generally avoided, but included
in a few “other” response categories. Furthermore, the
Bjerre et al. BMC Cardiovascular Disorders          (2018) 18:212 Page 3 of 10
respondents were given the opportunity to leave com-
ments after selected sections of the questionnaire.
Pre-test: Expert review
The first method used in evaluating the questionnaire was
an informal, individually-based expert review. Four par-
ticipating cardiologists or cardiology fellows (ACR, MS, JP
and LS) and one device technician (JDP) each independ-
ently conducted a review and determined whether he/she
found the items sufficient relative to the questionnaire’s
aims, or if a questionnaire item was problematic. Follow-
ing adjustments based on these evaluations, the question-
naire was reviewed by a senior questionnaire expert (JC),
independent from the study group. Adjustments following
this expert review included minor modifications like intro-
ducing help texts to emphasize different recall periods,
using continuous response categories for questions on
time to resumption of driving following ICD implantation
and/or shock, and strongly urging respondents to
complete the questionnaire with a next of kin.
Pre-test: Cognitive interviews
Further examination of content validity and refinement of
items was done by cognitive interviewing of 28 ICD
patients in the outpatient clinic at all six ICD implanting
centres in Denmark (range: 4–6 patients/centre). We
chose to include ICD patients from all five regions of
Denmark to capture any geographic variance potentially
influencing questionnaire responses (Capital Region: 8
participants; Zealand Region: 4 participants; Southern
Denmark: 5 participants; Central Jutland: 6 participants;
Northern Jutland: 5 participants). On a given day, ICD pa-
tients visiting the outpatient clinic were approached in a
random manner and were excluded only if they did not
have a valid driver’s licence at time of ICD implantation. A
retrospective verbal probing approach was used, and the
probe questions were asked following completion of each
of the four sections of the questionnaire. Probes were both
scripted (e.g. “What does the term ICD shock mean to
you?”) and spontaneous (e.g. “I noticed that you hesitated.
Can you tell me what you were thinking?”). We utilized
Tourangeau’s 4-stage cognitive model, investigating: (1)
comprehension of the question; (2) retrieval of informa-
tion (recall strategy); (3) decision processes; and (4) re-
sponse processes [17]. Another significant focus in these
cognitive interviews was recognizing any reluctance in an-
swering questions about adherence to driving restrictions
and further, to identify what wording to use to make
respondents trust that information on non-adherence
would remain anonymous.
Head-investigator (JB) performed all the cognitive
interviews over a period of 16 weeks as an iterative
process with alterations of the questionnaire items where
necessary after each interview session. The initial five
rounds of cognitive interviews were conducted using the
web-based questionnaire, while the patients in the last
round of interviews were presented with the paper for-
mat questionnaire. After the cognitive interviews at each
implanting centre were completed, JB reviewed and
summarized the results and determined whether, for
each tested item, significant problems had been detected.
Throughout the interviewing process, the frequency of
problems encountered per patient interviewed, declined
(Additional file 2: Table S2).
Pilot test
The nationwide Danish Pacemaker and ICD registry was
used to identify all individuals with a first-time ICD
implantation in the period January 1, 2013 to November
30, 2016. Among these, 50 individuals were randomly
selected to participate in the pilot test and were subse-
quently matched with up-to-date address data from the
Danish Civil Person Register. Invitations to participate in
the study were mailed on February 23, 2017. Participants
were urged to complete the web-based questionnaire,
however, an option to request a paper version was
presented (Additional file 3, translated from Danish).
Following 3 weeks, a reminder was mailed to all non
-responders including a paper version of the question-
naire and a prepaid return envelope. The web-based ques-
tionnaire software SurveyXact, developed by Rambøll A/S
and approved for research purposes by the Capital Region
of Denmark and the Danish Data Protection Agency, was
used for data collection [18]. The pilot test was terminated
on April 13, 2017, after 7 weeks’ data collection. All paper
responses were entered into the web-based questionnaire
software by double manual data entry to reduce the con-
sequences of potential human errors.
Test-retest
To investigate the reproducibility of the questionnaire
items, we invited the first 25 pilot test participants who
responded to the questionnaire to complete the ques-
tionnaire again at 3 weeks after their first response. This
timeframe was deemed appropriate as to avoid memory
effects positively influencing the test-retest reliability. No
reminders were distributed to test-retest participants.
Statistical analyses
Results of the pilot test were summarized by reporting
responses on selected questionnaire items by available
case analysis, thus, the number of responses to each
question may vary. For descriptive analyses, categorical
variables are reported as percentages and continuous
variables are presented as medians with interquartile
range. Test-retest agreement was investigated by kappa
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coefficients or weighted kappa coefficients for categor-
ical variables and intraclass correlation coefficients for
continuous variables. All analyses were performed using
SAS (version 9.4, Cary, NC, USA).
Results
Focus group interviews
All concepts already identified from the literature were
confirmed in the focus groups interviews, excluding the
effect of driving restrictions on self-esteem. In addition,
we discovered that many of the participants had changed
their driving behaviour in some way after ICD implant-
ation: For example, some patients reported being extra
cautious when driving with children (e.g. driving at
slower speed, avoiding the overtaking lane on highways)
or avoiding highways altogether. Also, a significant
proportion of primary prevention patients called for
more information about potential driving restrictions in
case of future ICD therapy and also being explained the
rationale behind the driving restrictions, as they saw
these as promoting factors for compliance with the
restrictions. Generally, in an anonymous setting, the par-
ticipants willingly volunteered information about not
adhering to the driving restrictions.
Pilot test
Among the 50 ICD patients (9 women (18%)) invited to
participate in the pilot test, 30 (60%) either responded
electronically or requested a paper version of the
questionnaire within 3 weeks. Following only one re-
minder, 39 participants (78%) completed the question-
naire (Fig. 2). Almost all web-based responses (85%)
came within 1 week. Median time for completing the
questionnaire was 9.5 min for the web-based responses
(IQR: 5.2–13.7 min).
Of the responders, 37 (97%) held a valid private
driver’s license for car, motorcycle or tractor (Group 1
drivers) prior to implantation and 11 (30%) held a valid
driver’s license for large vehicles or any professional
driving (Group 2 drivers) (Fig. 3). However, only two re-
sponders had actively used their professional license dur-
ing the 6 months prior to ICD implantation – both were
truck drivers. The most common occasions (> 75%) for
driving prior to ICD implantation included practical
errands, visits to family and friends and in relation with
leisure activities, while eight (22%) drove during work
hours (Table 1).
Only half of the respondents remembered being in-
formed of any driving restrictions for private driving.
Of these, two thirds reported they had solely been in-
formed verbally (Table 2). The information given by
health personnel on driving following implantation as
recalled by the patients ranged from resuming to
drive immediately after ICD implantation to never to
drive again. Still, patients were overall satisfied with
the communication of the driving restrictions. Among
the responders actively driving professionally prior to
ICD implantation, only one (50%) could remember
being told never to drive professionally again. Of the
ICD patients having experienced an appropriate ICD
shock, three out of four remembered having been ver-
bally informed not to drive for 3 months.
Following ICD implantation, 35 (95%) of responders
with a driver’s license resumed private driving whereas
professional driving was resumed by one responder
(Fig. 3). Overall median time to resumption of driving was
14 days (interquartile range: 2–60) while professional
Fig. 2 Pilot test flow chart. Overview of distribution of the questionnaire. Initial distribution included a patient-specific link to the web-
based questionnaire, whereas the second distribution additionally included a paper version of the questionnaire
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driving was resumed at 8months. Among patients being
instructed of a minimum 1-month driving ban, either after
ICD implantation or ICD shock, three patients (25%) ad-
mitted they had been driving although restricted. None had
experienced an ICD shock or loss of consciousness while
Fig. 3 Driving characteristics before and after ICD implantation. Overview of respondents with private and professional/large vehicle driver’s licences
before ICD implantation, their resumption of driving following ICD implantation as well as non-adherence to the driving restrictions
(defined as restrictions of minimum 1 month’s duration following either ICD implantation or ICD therapy)
Table 1 Driving characteristics before ICD implantation
Driving characteristics No. of patients (%)
Private driver’s license (n = 38) 37 (97%)
Professional/large vehicle driver’s license (n = 37) 11 (30%)
Purpose of professional/large vehicle driver’s licence (n = 10)
Truck driver 4 (40%)
Bus driver 2 (20%)
Taxi driver 0
Other, including private use 4 (40%)
Use of professional/large vehicle driver’s licence six
months prior to implantation (n = 10)
2 (20%)
Other members of the household hold driver’s
license (n = 37)
26 (70%)
Typical occasions for driving six months prior to implantation (n = 37)
Professional driving or driving of large vehicle
during work hours
2 (5%)
During work hours 8 (22%)
To/from work/school 16 (43%)
In relation with practical errands 31 (84%)
To visit family and friends 33 (89%)
In relation with leisure activities 28 (76%)
Did not drive during the period 2 (5%)
Average hours/week driving prior to implantation (n = 35)
< 1 h a week 0
1–3 h a week 12 (34%)
4–6 h a week 7 (20%)
7–9 h a week 7 (20%)
10 h a week or more 9 (26%)
Table 2 Information on driving restrictions following ICD
implantation, as reported by patients
Variable No. of patients (%)
Informed about driving restrictions (n = 37)
Yes 18 (49%)
No 7 (19%)
Cannot remember 12 (32%)
Way information was given (n = 18)
Only verbally 12 (67%)
Only in writing –
Both verbally and in writing 6 (33%)
Information given (n = 18)
Resume driving immediately 1(6%)
Resume when I felt ready 1 (6%)
Resume after 1 week 4 (22%)
Resume after 1 month 3 (17%)
Resume after 3 months 8 (44%)
Resume after 6 months –
Never to drive again 1 (6%)
Level of satisfaction with information given (n = 18)
Very satisfied or satisfied 14 (78%)
Neutral 4 (22%)
Dissatisfied or very dissatisfied –
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driving, but two patients (6%) had experienced dizziness
and four patients (11%) had experienced palpitations while
driving. None of these events necessitated stopping the ve-
hicle or resulted in a motor vehicle accident.
Overall, patients had not altered their driving behav-
iour after ICD implantation. Only four patients (12%)
were afraid of having an ICD shock while driving, and
only one patient was nervous about driving or tried to
avoid highways as a consequence of ICD implantation.
None avoided driving alone or driving with children in
the car. Among the 11 patients with a significant driving
restriction (defined as ≥1 month), six (55%) stated that
the driving restrictions in some way had impeded with
their daily life and 45 and 33% responded that they had
been very limited in maintaining employment and get-
ting to/from work, respectively.
Test-retest
Of the 25 responders invited to participate in a test-
retest questionnaire, 19 (75%) responded within 3 weeks.
Kappa statistics found that 69% of the analyzed ques-
tionnaire items had substantial agreement, with kappas
or weighted kappas above 0.6, whereof 37.5% were above
0.8. (Additional file 4: Table S3). Generally, the kappas
with moderate (0.4–0.6) and fair agreement (0.2–0.4)
were found in the section on the driving restrictions’ in-
fluence on factors associated with QoL. In one item, the
only test-retest response was reverse, rendering a kappa
of 0. The intraclass correlation coefficient for time to re-
sumption of private driving following ICD implantation
and appropriate ICD shock was 0.98 and 1.00, respect-
ively, whereas the time to resumption of professional
driving could not be analyzed as the item only had one
test-retest response.
Discussion
Through a thorough developmental and testing process,
we have constructed a questionnaire aimed to investigate
ICD patients’ perspective on driving, including the infor-
mation received on driving following ICD implantation
and/or ICD shock, adherence to the driving restrictions,
episodes of cardiac symptoms while driving, the driving
restrictions’ influence on factors associated with QoL,
and alterations of driving behaviour after ICD implant-
ation. The pilot test administered to 50 randomly
selected Danish ICD patients achieved a response rate of
78% over seven-week period with only one reminder.
The high response rate confirms our understanding that
this is an area of great importance to ICD patients and
furthermore implies a high level of target population
comprehension of the developed questionnaire.
Our pilot test results support previous research report-
ing poor communication between health professionals
and ICD patients on the subject of driving [7, 9, 19]:
20% reported they had not received any information on
driving restrictions after ICD implantation. However, in
the final questionnaire it will be important to stratify
these data on both ICD indication, as well as time since
ICD implantation to account for time as a recall bias. In
fact, 30% of responders reported they could not remem-
ber if they had been informed on any driving restric-
tions. Nevertheless, given that professional guidelines
recommend driving restrictions after ICD implantation
and ICD therapy, it is pivotal for patient compliance that
these restrictions are communicated to the patients. A
recent study found that a systematic counselling pro-
gram before patient discharge had a positive impact on
both patient compliance with treatment, as well as pa-
tient QoL [20]. Similar effects could be anticipated in
terms of compliance with driving restrictions and our re-
sults will quantify the need for potential improvements
in this area.
In the focus group interviews, some primary preven-
tion ICD patients called for information at the time of
ICD implantation on potential driving restrictions in
case of future ICD shocks. However, to reduce respond-
ent burden and because we considered the concepts
would be more suitable for investigation in a qualitative
method, we chose not to include these concepts in the
final questionnaire.
Previous studies suggest many ICD patients resume
driving earlier than instructed [7, 8, 10, 11]. Prior to
developing the questionnaire, we had concerns regard-
ing the patients’ willingness to answer questions on
sensitive matters such as non-adherence to driving re-
strictions. However, throughout the developmental
process including both focus group and cognitive in-
terviews, we found that this was not a substantial
problem. Following recommendations from pre-test
participants, we included multiple statements affirm-
ing that information would not be forwarded to the
authorities. In the pilot test, 25% of responders with a
significant driving ban admitted they had been driving
while restricted. This is comparable to previously pub-
lished results [8], thus, we feel assured that respon-
dents not answering truthfully is not a major issue. To
capture both ICD patients knowingly and unknowingly
driving during the guideline-recommended restricted
period, we also included questions about time to re-
sumption of both private and professional driving after
ICD implantation, as well as after ICD shock. For ex-
ample, one Group 2 driver who believed he had not
received information on restrictions for professional
driving, stated that this had been resumed 8 months
following implantation.
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This questionnaire was not designed to measure
overall QoL in an ICD population, but rather to inves-
tigate if the driving restrictions themselves had influ-
enced factors associated with QoL. Particularly, the
risk of losing the ability to earn an income as a profes-
sional driver has not been systematically investigated
previously. Thus, we included a separate question to
professional drivers on whether they had lost their job
as a result of the driving restrictions. In the small pilot
test sample, this was not the case for any of the two
truck drivers. However, more than half of the respon-
dents with a driving restriction longer than 1 month
said the restrictions had impeded with their daily life,
specifically maintaining employment and getting to/
from work. Thus, the driving restrictions can defin-
itely temporarily restrict ICD patients’ ability to work
and thus affect their household economic status, even
if they are not professional drivers.
Focus groups revealed that some ICD patients alter
their driving behaviour because of ICD implantation in
other aspects than quantity of time spent driving. Conse-
quently, we chose to include questions on this specific
aim in the questionnaire. However, in the small pilot
sample, only 12% expressed concerns about having an
ICD shock while driving and only one respondent
expressed avoidance behaviour with regards to driving
on highways. By linking the final questionnaire with the
ICD registry, the future results of the questionnaire can
relevantly be stratified by ICD indication as well as his-
tory of ICD shocks.
The pilot test achieved a response rate of 78%, and im-
pressively, more than two-thirds of the responses were
web-based. This number was higher than anticipated in a
population with a mean age around 62 years [21], and de-
creased the investigator’s risk ofmaking typingmistakes as
well as the burden of manually entering paper responses
into the web-based questionnaire database. Further,
web-based questionnaires in general reduce respondent
burden as the completed questionnaires do not need to be
mailed. To capture a wide range of the target population
and not exclude individuals with limited computer skills,
we chose to move forward with both modalities of data
collection.
Test-retest found almost perfect agreement in nearly
40% of the items and substantial agreement in 31% of
all items [22]. The generally high reliability indicates
that, despite the high mean age and disease burden in
the population, the responses produced by the ques-
tionnaire are representative and stable over time.
However, the limit for when kappa statistics are in suf-
ficient agreement are both subjective and arbitrary,
and furthermore, our small sample of 19 test-retest re-
spondents should be considered. Besides, due to the
branching of the questionnaire, we were unable to
retest all items regarding rare events, for example the
items on cardiac symptoms while driving.
Study limitations and future perspectives
Questionnaire studies pose some significant inherent
limitations. Many relate to poor question design (e.g.
problems with wording, leading questions, scale formats)
or questionnaire design (e.g. formatting problems, too
long or complex questionnaire) which we have tried to
overcome by thorough pre-testing, but some questions
will inevitably be misinterpreted. Moreover, though the
focus group participants were generally good at recalling
specific information from the time of ICD implantation,
recall bias cannot be excluded. Also, social desirability
may contribute to respondents giving untrue answers,
particularly to the questions related to adherence,
although focus group and cognitive interviews demon-
strated the contrary. Lastly, we naturally only included
patients who were alive at the time of questionnaire
administration, introducing a healthy participant bias
which, similarly to the non-response bias, covers the fact
that responders (or survivors) could differ significantly
from the non-responders.
The questionnaire was developed specifically for use in
a nationwide cohort of Danish ICD patients and the final
questionnaire has been administered to more than 3900
individuals. Due to the unique Danish administrative
registries, we will be able to link the final questionnaire
results with reliable clinical and demographic informa-
tion, including indication for ICD implantation, socio-
economic status, and comorbidities. Importantly, linkage
with the nationwide registries also allows comparison be-
tween responders and non-responders, a major strength
in a questionnaire study.
In this pilot study, however, the results have not been
linked with relevant clinical data and we were therefore
not able to stratify results on important clinical informa-
tion such as cardiac resynchronization status, pharmaco-
logical treatment and comorbidities such as diabetes. All
of these will be relevant to include in the final question-
naire study when investigating factors associated with
the risk of ICD therapy while driving, as they have been
found to affect the risk of adverse clinical outcomes, in-
cluding ICD therapy [21, 23–25]. Other limitations of
the current study include lack of information on heart
failure biomarker levels and home monitoring status
which are also expected to affect clinical outcomes,
especially in primary prevention patients with a cardiac
resynchronization device [26–28].
Conclusion
In summary, we have developed a comprehensive ques-
tionnaire on the patient’s perspective on driving and
driving restrictions following ICD implantation, with
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good content validity and acceptable patient and investi-
gator burden. From pilot test results, we anticipate that
the final questionnaire, distributed to > 3900 ICD
patients, will very likely reach a response rate above 60%
and provide much-needed data about information on,
adherence to and impact of driving restrictions in a
large, nationwide, contemporary cohort of ICD patients.
We believe these results will be valuable and potentially
identify problematic areas in need of further focus or
interventions.
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